Evidence-Based Treatment Guidelines for Body Dysmorphic Disorder
Cognitive Behavioral Therapy (CBT) incorporating Exposure with Response Prevention (ERP) should be offered as first-line treatment for BDD, with SSRIs as second-line for moderate-to-severe cases or when CBT is unavailable or ineffective. 1
First-Line Treatment: Cognitive Behavioral Therapy
CBT with ERP is the gold-standard first-line treatment based on NICE guidelines and supported by strong evidence showing large effect sizes (Cohen's d = 1.22) in reducing BDD symptoms 1. The evidence demonstrates CBT's superiority over waitlist and psychological control conditions, with additional benefits for depression and insight 1.
CBT Structure and Delivery
A typical course consists of 12-22 weekly sessions, though more severely impaired patients may require extended treatment 1. The therapy follows three distinct phases:
- Sessions 1-3: Psychoeducation and formulation
- Session 4 onwards: Exposure with response prevention and/or behavioral experiments
- Final 2 sessions: Relapse prevention
Key CBT Components
The core therapeutic mechanism is ERP, where patients gradually confront feared situations while resisting compulsive safety behaviors 1. For example, someone preoccupied with ear appearance would practice going out with hair tied up, without hats or concealing behaviors. Through repeated exposure, anxiety extinguishes and maladaptive beliefs are challenged.
Family involvement is essential - parents/carers should be included at minimum during psychoeducation phases 1. Treatment must be developmentally adapted for younger patients.
Treatment Outcomes
Recent naturalistic data from 140 young people receiving specialist CBT (mean 17.2 sessions) showed 79% response rates and 59% full or partial remission 1. Importantly, unmedicated patients (n=37) achieved similar outcomes, confirming CBT's standalone efficacy. These real-world results are more encouraging than the initial RCT showing only 40% response rates, likely reflecting differences in baseline severity 1.
Second-Line Treatment: Selective Serotonin Reuptake Inhibitors
SSRIs should be used for patients aged 12-18 years with moderate-to-severe functional impairment who have inadequate CBT response, or when CBT is unavailable 1. This recommendation comes with important caveats:
- The 12-18 age range is somewhat arbitrary with limited supporting evidence 1
- In practice, CBT for BDD is rarely available, making SSRIs more commonly prescribed 1
- High doses are typically required - higher than standard antidepressant dosing 2
- Protracted treatment periods are needed to establish full benefit 2
Augmentation Strategies for Treatment-Resistant Cases
When SSRIs prove inadequate, consider:
Critical caveat: These augmentation strategies lack large-scale RCT support and BDD is not an approved indication for these medications 2.
Combined Treatment Approach
In routine clinical practice, 72% of young people receive concurrent CBT and SSRIs 1. While the relative efficacy and optimal sequencing of monotherapy versus combination treatment remains formally unstudied 1, multimodal treatment appears effective with 79% response rates in naturalistic settings 1.
Treatment Considerations for Severe Cases
Patients with greater functional impairment may require:
- Extended CBT courses (potentially >22 sessions) 1
- Home-based CBT sessions 1
- Medication optimization with higher-dose SSRIs 1
Critical Treatment Pitfalls to Avoid
Cosmetic Procedures Are Contraindicated
Cosmetic procedures should not be recommended - evidence shows poor psychological outcomes in BDD patients, with most feeling disappointed or shifting concerns to other features 1. This precipitates mental health deterioration rather than improvement. Young people may attempt dangerous home-based "treatments" when professional procedures are unavailable 1.
Engagement Challenges
Poor insight is common and complicates engagement 1. Avoid polarizing physical versus psychological explanations. Instead, frame treatment goals around reducing distress, improving quality of life, and building self-confidence. Use motivational interviewing techniques throughout therapy 1.
Risk Assessment Is Mandatory
BDD carries exceptionally high suicide risk - approximately 50% of young people report self-harm, and BDD is considered a particularly high-risk psychiatric disorder 1. Self-harm may be appearance-related (e.g., skin-picking to remove blemishes, applying bleach to skin) or related to mood dysregulation 1.
Emerging Treatment Modalities
Digital CBT shows promise for improving access, with mean difference of -5.89 (95% CI: -20.38 to 8.60) compared to waitlist, though slightly less potent than traditional face-to-face CBT 3. Online and telephone-assisted therapy formats warrant further exploration 2.
Evidence Gaps and Clinical Reality
Despite strong evidence for CBT, access remains severely limited in most healthcare systems 1. The field lacks:
- Any pharmacological RCTs in young people 1
- Head-to-head comparisons of CBT versus SSRIs 1
- Studies on optimal treatment sequencing 1
Given these limitations and the high morbidity of untreated BDD, pragmatic use of available treatments (either CBT or SSRIs) is justified rather than delaying treatment while awaiting ideal circumstances.